Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceutical’s (RCE) anti-infective drugs have demonstrated positive test results in combatting SARS-CoV-2 or, the COVID-19 virus
- The live animal studies concluded both RCE’s R327 and R529 medications reduced viral load present in the blood of infected hamsters compared to a placebo group
- 40 hamsters were tested, each receiving higher or lower treatment doses of the drugs, respectively, or a placebo saline wash
- While the study offers a good indication of the potential for nasal administration of Recce’s anti-infective compounds, further testing on larger animals must be completed before it can be deemed fully safe and effective
- RCE shares are up modestly by 1.85 per cent, trading at $1.10
Recce Pharmaceutical’s (RCE) anti-infective drugs have demonstrated positive test results in combatting SARS-CoV-2 or, the COVID-19 virus.
Live animal studies were completed on 40 Syrian golden hamsters to test the effectiveness of RCE’s R327 and R529 medications against the virus.
The hamsters were all infected with SARS-CoV-2 at the beginning of the trial and individually treated with either a higher or lower dose of the medication or a placebo saline wash.
Findings concluded both RCE’s R327 and R529 medications reduced the viral load, or the measure of total virus particles, present in the blood of infected hamsters compared to the placebo group.
While the study offers a good indication of the potential for nasal administration of Recce’s anti-infective compounds, further testing on larger animals must be completed before it can be deemed fully safe and effective.
A company spokesperson says a concurrent COVID-19 study on ferrets is underway and seeking to explore further methods of adminstering the medication and higher dose concentrations.
Data from these studies are expected in early 2021.
RCE shares are up modestly by 1.85 per cent at 9:14 am AEDT, trading at $1.10.
